Commercialization of methods and reagents for high-throughput single cell analysis
Award amount
$1,146,224Program and phase
SBIR · Phase IIAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- FLUENT BIOSCIENCES INC
- Proposal award date
- 2023-09-01
- Contract end date
- 2025-07-31
- UEI
- DA7UPTVQMG73
- Solicitation number
- PA22-176
- Topic code
- 400
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- New tools for highly accessible single cell RNA sequencing
- Custom assays for personalized, longitudinal monitoring of circulating tumor DNA using PIPSenSeq
- PIPsceq: powering single cell RNA sequencing into the million cell era
- Anti-cancer drug screening enabled by Pre-templated Instant Partitions and single cell RNA sequencing
- Custom assays for personalized, longitudinal monitoring of circulating tumor DNA using PIPSenSeq
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Platform for Optimizing Yield and Quality of Therapeutic AAV Vector Manufacturing via Synthetic Helper Genes
- Ultra-low-temperature (6 K) static NMR-DNP for metalloproteins, proteins in cells, and materials
- Dynamical Diffraction Analysis for 3D Electron Crystallography
- Synthetic biology approaches for bio-orthogonal labeling of circular RNAs
- Break Wave lithotripsy to fragment large kidney stones
Research funding history
6 SBIR/STTR records share this UEI (2019–2023). Reported award amounts total $5,742,910. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services